Intercept Pharmaceuticals Inc (ICPT)

110.87 +3.39  +3.15% NASDAQ Dec 9, 20:00 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
02/28/2020 08:30 EST Misc Intercept Pharmaceuticals Inc Fourth Quarter Earnings Conference Call in 2019
02/28/2020 Earnings Intercept Pharmaceuticals Inc Fourth Quarter Earnings in 2019 Release
11/05/2019 08:30 EST Misc Intercept Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2019
11/05/2019 Earnings Intercept Pharmaceuticals Inc Third Quarter Earnings for 2019 Release
08/07/2019 08:30 EDT Misc Intercept Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2019
08/07/2019 Earnings Intercept Pharmaceuticals Inc Second Quarter Earnings in 2019 Release
06/20/2019 10:00 EDT Misc Intercept Pharmaceuticals Inc Annual General Meeting in 2018
05/08/2019 08:30 EDT Misc Intercept Pharmaceuticals Inc First Quarter Earnings Conference Call in 2019
05/08/2019 Earnings Intercept Pharmaceuticals Inc First Quarter Earnings in 2019 Release
03/01/2019 Misc Intercept Pharmaceuticals Inc Annual Report in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.interceptpharma.com
  • Investor Relations URL: http://ir.interceptpharma.com/index.cfm
  • HQ State/Province: New York
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: Feb. 28, 2020
  • Last Earnings Release: Nov. 05, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. Intercept owns worldwide rights to OCA outside of China, where it has licensed out the product to Sumitomo Dainippon Pharma.

Top Fund Holders

Symbol Name Weighting
CIG4924 CI Global Health Sciences Corp Cl Y 5.16%
FBT First Trust NYSE Arca Biotech ETF 4.82%
BBP Virtus LifeSci Biotech Products ETF 3.27%
XBI SPDR® S&P Biotech ETF 2.26%
VLLIX Value Line Larger Companies Focus Instl 2.17%
BFONX Biondo Focus Investor 1.80%
VLIIX Value Line Capital Appreciation Instl 1.65%
LAUCX Columbia Acorn USA C 1.29%
LABU Direxion Daily S&P Biotech Bull 3X ETF 1.20%
RYJ Invesco Raymond James SB-1 Equity ETF 0.87%
FIJYX Fidelity Advisor® Biotechnology Z 0.74%
ISMD Inspire Small/Mid Cap Impact ETF 0.31%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.